Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
3.99
USD
|
+2.31%
|
|
+7.84%
|
+40.49%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
746.8
|
217.6
|
294.2
|
475.1
|
-
|
-
|
Enterprise Value (EV)
1 |
746.8
|
217.6
|
294.2
|
475.1
|
475.1
|
475.1
|
P/E ratio
|
-11
x
|
-17.6
x
|
-2.65
x
|
-4.44
x
|
-5.48
x
|
-13.1
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
591
x
|
139
x
|
-
|
167
x
|
15.8
x
|
5.12
x
|
EV / Revenue
|
591
x
|
139
x
|
-
|
167
x
|
15.8
x
|
5.12
x
|
EV / EBITDA
|
-9.95
x
|
-2.64
x
|
-3.44
x
|
-5.82
x
|
-8.01
x
|
-16.9
x
|
EV / FCF
|
-
|
-
|
-3.89
x
|
-5.84
x
|
-7.87
x
|
-16.3
x
|
FCF Yield
|
-
|
-
|
-25.7%
|
-17.1%
|
-12.7%
|
-6.15%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
103,003
|
103,118
|
103,575
|
119,084
|
-
|
-
|
Reference price
2 |
7.250
|
2.110
|
2.840
|
3.990
|
3.990
|
3.990
|
Announcement Date
|
3/29/22
|
3/24/23
|
3/22/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
1.263
|
1.565
|
-
|
2.85
|
30.14
|
92.79
|
EBITDA
1 |
-75.03
|
-82.55
|
-85.5
|
-81.6
|
-59.3
|
-28.1
|
EBIT
1 |
-81.21
|
-84.58
|
-100
|
-104.6
|
-88.1
|
-38.83
|
Operating Margin
|
-6,429.77%
|
-5,404.35%
|
-
|
-3,669.77%
|
-292.32%
|
-41.85%
|
Earnings before Tax (EBT)
1 |
-26.48
|
-11.96
|
-110.8
|
-106.6
|
-92.99
|
-42.45
|
Net income
1 |
-26.48
|
-11.96
|
-110.8
|
-102.9
|
-88.88
|
-42.45
|
Net margin
|
-2,096.36%
|
-764.54%
|
-
|
-3,611.2%
|
-294.88%
|
-45.75%
|
EPS
2 |
-0.6600
|
-0.1200
|
-1.070
|
-0.8983
|
-0.7283
|
-0.3050
|
Free Cash Flow
1 |
-
|
-
|
-75.58
|
-81.4
|
-60.4
|
-29.2
|
FCF margin
|
-
|
-
|
-
|
-2,855.81%
|
-200.4%
|
-31.47%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/29/22
|
3/24/23
|
3/22/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
0.241
|
0.177
|
0.233
|
1.301
|
0.031
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
0.597
|
2.828
|
3.193
|
EBITDA
|
-19
|
-20.1
|
-18.18
|
-15.02
|
-19.98
|
-20.35
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-20.54
|
-21.63
|
-21.76
|
-18.53
|
-23.49
|
-20.79
|
-22.51
|
-26.73
|
-24.62
|
-26.18
|
-25.9
|
-27.21
|
-27.7
|
-26.14
|
-25.83
|
Operating Margin
|
-8,524.07%
|
-12,218.64%
|
-9,340.34%
|
-1,424.37%
|
-75,787.1%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-4,640.37%
|
-924.04%
|
-809.17%
|
Earnings before Tax (EBT)
1 |
-31.56
|
42.58
|
-19.83
|
36.87
|
-25.28
|
-3.72
|
-36.97
|
-22.71
|
-26
|
-25.11
|
-25.78
|
-27.09
|
-27.59
|
-26.19
|
-25.72
|
Net income
1 |
-31.56
|
42.58
|
-19.83
|
36.87
|
-25.28
|
-3.72
|
-36.97
|
-22.71
|
-26
|
-25.11
|
-25.78
|
-27.09
|
-27.59
|
-26.19
|
-25.72
|
Net margin
|
-13,096.68%
|
24,059.32%
|
-8,511.59%
|
2,833.82%
|
-81,551.61%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-4,622.19%
|
-925.95%
|
-805.53%
|
EPS
2 |
-0.7200
|
0.4100
|
-0.1900
|
0.3500
|
-0.2500
|
-0.0400
|
-0.3600
|
-0.2200
|
-0.2500
|
-0.2400
|
-0.2250
|
-0.2275
|
-0.2300
|
-0.2175
|
-0.2133
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/12/21
|
3/29/22
|
5/13/22
|
8/12/22
|
11/10/22
|
3/24/23
|
5/12/23
|
8/14/23
|
11/9/23
|
3/22/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-75.6
|
-81.4
|
-60.4
|
-29.2
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
0.22
|
1.05
|
2.28
|
16
|
5.77
|
1.35
|
Capex / Sales
|
17.42%
|
66.96%
|
-
|
561.34%
|
19.13%
|
1.45%
|
Announcement Date
|
3/29/22
|
3/24/23
|
3/22/24
|
-
|
-
|
-
|
Last Close Price
3.99
USD Average target price
8
USD Spread / Average Target +100.50% Consensus |
1st Jan change
|
Capi.
|
---|
| +40.49% | 475M | | +1.51% | 42.75B | | +49.22% | 41.61B | | +8.57% | 41.34B | | -12.36% | 26.59B | | +8.92% | 25.49B | | -25.13% | 18.12B | | +29.17% | 12.24B | | -3.12% | 11.76B | | +6.35% | 11B |
Other Biotechnology & Medical Research
|